Clovis Oncology To Present At September Conferences In Boston And New York

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Company management will participate in the following two investor conferences during the month of September:

On September 6, Erle T. Mast, the Company’s CFO, will present at the Stifel Nicolaus 2012 Healthcare Conference at 11:30 a.m. ET at the Four Seasons Hotel in Boston.

On September 10, Patrick J. Mahaffy, the Company’s president and CEO will present at the Morgan Stanley Global Healthcare Conference at 4:10 p.m. ET at the Grand Hyatt in New York City.

Live webcasts of the corporate presentations at the Stifel Nicolaus and Morgan Stanley conferences will be accessible through the investor relations section of the Company’s website at www.clovisoncology.com. Following the live presentation, a replay of each webcast will be available on the Company’s website for 30 days.

About Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in San Francisco, California and Cambridge, UK.

Copyright Business Wire 2010

If you liked this article you might like

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Clovis Up on Priority Review Status for Ovarian Cancer Therapy -- Biotech Mover

Clovis Up on Priority Review Status for Ovarian Cancer Therapy -- Biotech Mover

What's Hot and What's Not: Cramer's 'Mad Money' Recap (Thursday 10/12/17)

What's Hot and What's Not: Cramer's 'Mad Money' Recap (Thursday 10/12/17)

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition